董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 汉雨生 | 男 | Founder, chairman of the board and chief executive officer | 44 | 未披露 | 未持股 | 2023-06-30 |
| Leo Li | 男 | Director and chief financial officer | 38 | 未披露 | 未持股 | 2023-06-30 |
| Wendy Hayes | 女 | Independent director | 53 | 未披露 | 未持股 | 2023-06-30 |
| Gang Lu | 男 | Director | 51 | 未披露 | 未持股 | 2023-06-30 |
| Min Jui Richard Shen | 男 | Independent director | 58 | 未披露 | 未持股 | 2023-06-30 |
| 张之宏 | 男 | Chief technology officer and director | 47 | 未披露 | 未持股 | 2023-06-30 |
| Licen Lisa Xu | 女 | Independent director | 57 | 未披露 | 未持股 | 2023-06-30 |
| Feng Deng | 男 | Director | 59 | 未披露 | 1188.02 | 2023-06-30 |
高管介绍
注：高管持股数取自最新公司公告
董事简历
中英对照 | 中文 | 英文- 汉雨生
-
汉雨生 是Biotechnology Co., Ltd 创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. Mr. Han has 18 years of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011. - 汉雨生 是Biotechnology Co., Ltd 创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
- Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. Mr. Han has 18 years of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.
- Leo Li
-
Leo Li ，自2019年第三季度起担任Burning Rock Biotech Limited首席财务官，自2020年第一季度起担任Burning Rock Biotech Limited董事。在加入Burning Rock Biotech Limited之前，他曾担任Weidai Ltd.（纽约证券交易所上市的中国领先的汽车支持融资解决方案提供商）的首席财务官。在加入wechat 之前，他曾担任远景骑士资本（Vision Knight Capital，简称VKC，专注于中国互联网驱动行业的私募股权基金）的投资董事和执行董事。加入VKC之前，他在Morgan Stanley Asia Limited 工作。他于2004年至2008年就读于牛津大学（University of Oxford），获得四年物理学硕士学位。他是特许金融分析师。
Leo Li,has served as Burning Rock Biotech Limited chief financial officer since the third quarter of 2019 and Burning Rock Biotech Limited director since the first quarter of 2020. Prior to joining Burning Rock Biotech Limited , Mr. Li served as the chief financial officer of Weidai Ltd., a NYSE-listed leading auto-backed financing solution provider in China. Prior to Weidai Ltd., Mr. Li served as an investment director and later an executive director of Vision Knight Capital, or VKC, a private equity fund focusing on China's internet-driven sectors. Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd. Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree. Mr. Li is a Chartered Financial Analyst. - Leo Li ，自2019年第三季度起担任Burning Rock Biotech Limited首席财务官，自2020年第一季度起担任Burning Rock Biotech Limited董事。在加入Burning Rock Biotech Limited之前，他曾担任Weidai Ltd.（纽约证券交易所上市的中国领先的汽车支持融资解决方案提供商）的首席财务官。在加入wechat 之前，他曾担任远景骑士资本（Vision Knight Capital，简称VKC，专注于中国互联网驱动行业的私募股权基金）的投资董事和执行董事。加入VKC之前，他在Morgan Stanley Asia Limited 工作。他于2004年至2008年就读于牛津大学（University of Oxford），获得四年物理学硕士学位。他是特许金融分析师。
- Leo Li,has served as Burning Rock Biotech Limited chief financial officer since the third quarter of 2019 and Burning Rock Biotech Limited director since the first quarter of 2020. Prior to joining Burning Rock Biotech Limited , Mr. Li served as the chief financial officer of Weidai Ltd., a NYSE-listed leading auto-backed financing solution provider in China. Prior to Weidai Ltd., Mr. Li served as an investment director and later an executive director of Vision Knight Capital, or VKC, a private equity fund focusing on China's internet-driven sectors. Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd. Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree. Mr. Li is a Chartered Financial Analyst.
- Wendy Hayes
-
Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
Wendy Hayes,serves as a member of Apollomics Inc. board of directors. Ms. Hayes serves on the boards of directors of multiple public companies, including SharkNinja, Inc. (NYSE: SN) since July 2023, SciClone Pharmaceuticals (Holdings) Ltd (HK: 6600) since March 2021, iHuman Inc. (NYSE: IH) since October 2020, Burning Rock Biotech Limited (NASDAQ: BNR) since June 2020 and Tuanche Limited (NASDAQ: TC) since November 2018. Ms. Hayes previously served on the board of TuSimple (Nasdaq: TSP) from December 2022 to December 2023, and Gracell Biotechnologies Inc. (NASDAQ: GRCL) from January 2021 to February 2023. From May 2013 to September 2018, Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes is a certified public accountant in the United States (California) and in China. Ms. Hayes received her bachelor's degree in international finance from the University of International Business and Economics in Beijing and received an MBA from Cheung Kong Graduate School of Business in Shanghai. - Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
- Wendy Hayes,serves as a member of Apollomics Inc. board of directors. Ms. Hayes serves on the boards of directors of multiple public companies, including SharkNinja, Inc. (NYSE: SN) since July 2023, SciClone Pharmaceuticals (Holdings) Ltd (HK: 6600) since March 2021, iHuman Inc. (NYSE: IH) since October 2020, Burning Rock Biotech Limited (NASDAQ: BNR) since June 2020 and Tuanche Limited (NASDAQ: TC) since November 2018. Ms. Hayes previously served on the board of TuSimple (Nasdaq: TSP) from December 2022 to December 2023, and Gracell Biotechnologies Inc. (NASDAQ: GRCL) from January 2021 to February 2023. From May 2013 to September 2018, Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes is a certified public accountant in the United States (California) and in China. Ms. Hayes received her bachelor's degree in international finance from the University of International Business and Economics in Beijing and received an MBA from Cheung Kong Graduate School of Business in Shanghai.
- Gang Lu
-
Gang Lu ， 2014年6月起担任Burning Rock Biotech Limited董事。2009年，他加入了Lenovo star （一家总部位于北京的风险投资公司），他现在是Lenovo star 的合伙人，领导医疗保健投资，专注于创新医药、生物和基因技术以及创新医疗服务领域。他持有西安电子科技大学的电磁工程学士学位和清华大学的工商管理硕士学位。
Gang Lu,has served as Burning Rock Biotech Limited director since June 2014. In 2009, Mr. Lu joined Legend Star, a venture capital headquartered in Beijing, and he is now a partner of Legend Star and leads investment in healthcare, specialized in the fields of innovative medicine, biological and genetic technology, and innovative medical service. Mr. Lu holds a bachelor's degree in electromagnetic engineering from Xidian University and a Master of Business Administration degree from Tsinghua University. - Gang Lu ， 2014年6月起担任Burning Rock Biotech Limited董事。2009年，他加入了Lenovo star （一家总部位于北京的风险投资公司），他现在是Lenovo star 的合伙人，领导医疗保健投资，专注于创新医药、生物和基因技术以及创新医疗服务领域。他持有西安电子科技大学的电磁工程学士学位和清华大学的工商管理硕士学位。
- Gang Lu,has served as Burning Rock Biotech Limited director since June 2014. In 2009, Mr. Lu joined Legend Star, a venture capital headquartered in Beijing, and he is now a partner of Legend Star and leads investment in healthcare, specialized in the fields of innovative medicine, biological and genetic technology, and innovative medical service. Mr. Lu holds a bachelor's degree in electromagnetic engineering from Xidian University and a Master of Business Administration degree from Tsinghua University.
- Min Jui Richard Shen
-
Min Jui Richard Shen ，自2020年6月起担任Burning Rock Biotech Limited独立董事。Shen博士是Pacific Biosciences of California, Inc.（高质量、高精度测序平台的领先供应商）的研发高级副总裁。他曾担任Omniome（一家私营初创公司，于2021年被Pacific Biosciences收购）的总裁。他是RS Technology Ventures, LLC（他于2016年创立的战略咨询和投资公司）的董事总经理。从2000年到2016年，他在Illumina, Inc.（生命科学工具公司的供应商）工作，在那里他担任许多职位，最后担任肿瘤学研究和开发副总裁。在加入Illumina公司之前，沈博士于1998年至2000年在分子诊断公司Myriad Genetics工作。他在加州大学洛杉矶分校获得生物化学学士学位，在路易斯安那州立大学医学中心获得生物化学和分子生物学博士学位。此外，他是the Parker H. Petit Institute for the Georgia Institute of Technology的生物工程和生物科学的外部顾问委员会成员。
Min Jui Richard Shen,has served as Burning Rock Biotech Limited independent director since June 2020. Dr. Shen is the managing director of RS Technology Ventures, LLC, a strategic advisory and investment company that he founded in 2016. From 2021 to 2022, Dr. Shen served as the senior vice president of research and development at Pacific Biosciences of California, Inc., a leading provider of high-quality and accurate sequencing platforms. From 2020 to 2021, Dr. Shen was Chief Product Officer and then the President of Omniome, a privately held start-up that was acquired by Pacific Biosciences of California, Inc. in 2021. Dr. Shen worked at Illumina, Inc., a life sciences tools provider, from 2000 to 2016. He served in many roles at Illumina, the last of which was vice president for oncology research and development. Before joining Illumina, Dr. Shen worked at Myriad Genetics, Inc., a molecular diagnostics company, from 1998 to 2000. Dr. Shen earned his bachelor's degree in biochemistry from University of California, Los Angeles, and his Ph.D. degree in biochemistry and molecular biology from Louisiana State University Medical Center. Additionally, Dr. Shen is a member of the External Advisory Board of the Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology. - Min Jui Richard Shen ，自2020年6月起担任Burning Rock Biotech Limited独立董事。Shen博士是Pacific Biosciences of California, Inc.（高质量、高精度测序平台的领先供应商）的研发高级副总裁。他曾担任Omniome（一家私营初创公司，于2021年被Pacific Biosciences收购）的总裁。他是RS Technology Ventures, LLC（他于2016年创立的战略咨询和投资公司）的董事总经理。从2000年到2016年，他在Illumina, Inc.（生命科学工具公司的供应商）工作，在那里他担任许多职位，最后担任肿瘤学研究和开发副总裁。在加入Illumina公司之前，沈博士于1998年至2000年在分子诊断公司Myriad Genetics工作。他在加州大学洛杉矶分校获得生物化学学士学位，在路易斯安那州立大学医学中心获得生物化学和分子生物学博士学位。此外，他是the Parker H. Petit Institute for the Georgia Institute of Technology的生物工程和生物科学的外部顾问委员会成员。
- Min Jui Richard Shen,has served as Burning Rock Biotech Limited independent director since June 2020. Dr. Shen is the managing director of RS Technology Ventures, LLC, a strategic advisory and investment company that he founded in 2016. From 2021 to 2022, Dr. Shen served as the senior vice president of research and development at Pacific Biosciences of California, Inc., a leading provider of high-quality and accurate sequencing platforms. From 2020 to 2021, Dr. Shen was Chief Product Officer and then the President of Omniome, a privately held start-up that was acquired by Pacific Biosciences of California, Inc. in 2021. Dr. Shen worked at Illumina, Inc., a life sciences tools provider, from 2000 to 2016. He served in many roles at Illumina, the last of which was vice president for oncology research and development. Before joining Illumina, Dr. Shen worked at Myriad Genetics, Inc., a molecular diagnostics company, from 1998 to 2000. Dr. Shen earned his bachelor's degree in biochemistry from University of California, Los Angeles, and his Ph.D. degree in biochemistry and molecular biology from Louisiana State University Medical Center. Additionally, Dr. Shen is a member of the External Advisory Board of the Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology.
- 张之宏
-
张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
Zhihong Zhang,Dr. Zhihong (Joe) Zhang served as Burning Rock Biotech Limited chief technology officer since March 2016. Prior to joining Burning Rock Biotech Limited , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005. - 张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
- Zhihong Zhang,Dr. Zhihong (Joe) Zhang served as Burning Rock Biotech Limited chief technology officer since March 2016. Prior to joining Burning Rock Biotech Limited , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.
- Licen Lisa Xu
-
Licen Lisa Xu是FlashDx Inc.（一家分子诊断即时护理解决方案公司）的首席商务官，以及Ribbon Biolab（一家专门生产合成dna的公司）的独立董事会成员。她曾担任罗氏诊断公司（Roche Holding AG的子公司，负责诊断测试、仪器和数字解决方案的开发）的战略产品管理和生命周期管理副总裁，以及Illumina公司的战略营销和产品管理副总裁。她拥有苏黎世大学（University of Zurich）的分子生物学博士学位和清华大学（Tsinghua University）的生物物理学硕士学位，并完成了宾夕法尼亚大学（University of Pennsylvania）沃顿商学院（Wharton business School）的企业高管教育项目。
Licen Lisa Xu,has served as Burning Rock Biotech Limited independent director since June 2022. Dr. Xu has over 16 years of experience in driving the productization and lifecycle for life science and biomedical products, from product concept and research to development and commercialization. She is the chief commercial officer of FlashDx Inc., a molecular diagnostics sample-to-answer solution company, and an independent board member of Ribbon Biolab, a company specialized in the production of synthetic DNAs. Dr. Xu served as a vice president on strategic product management and lifecycle management at Roche Diagnostics, a subsidiary of Roche Holding AG for the development of diagnostic tests, instruments and digital solutions, and a vice president on strategic marketing and product management at Illumina Inc. Dr. Xu has a Ph.D. degree in molecular biology from University of Zurich and a master of science degree in biophysics from Tsinghua University, and completed the business executive education program from Wharton Business School, University of Pennsylvania. - Licen Lisa Xu是FlashDx Inc.（一家分子诊断即时护理解决方案公司）的首席商务官，以及Ribbon Biolab（一家专门生产合成dna的公司）的独立董事会成员。她曾担任罗氏诊断公司（Roche Holding AG的子公司，负责诊断测试、仪器和数字解决方案的开发）的战略产品管理和生命周期管理副总裁，以及Illumina公司的战略营销和产品管理副总裁。她拥有苏黎世大学（University of Zurich）的分子生物学博士学位和清华大学（Tsinghua University）的生物物理学硕士学位，并完成了宾夕法尼亚大学（University of Pennsylvania）沃顿商学院（Wharton business School）的企业高管教育项目。
- Licen Lisa Xu,has served as Burning Rock Biotech Limited independent director since June 2022. Dr. Xu has over 16 years of experience in driving the productization and lifecycle for life science and biomedical products, from product concept and research to development and commercialization. She is the chief commercial officer of FlashDx Inc., a molecular diagnostics sample-to-answer solution company, and an independent board member of Ribbon Biolab, a company specialized in the production of synthetic DNAs. Dr. Xu served as a vice president on strategic product management and lifecycle management at Roche Diagnostics, a subsidiary of Roche Holding AG for the development of diagnostic tests, instruments and digital solutions, and a vice president on strategic marketing and product management at Illumina Inc. Dr. Xu has a Ph.D. degree in molecular biology from University of Zurich and a master of science degree in biophysics from Tsinghua University, and completed the business executive education program from Wharton Business School, University of Pennsylvania.
- Feng Deng
-
Feng Deng， 自2006年7月起担任公司董事。自2005年12月起担任Northern Light Venture Capital（一家由他联合创立的风险投资公司）管理董事。他持有清华大学电子工程理学学士和硕士学位；南加利佛尼亚大学计算机工程硕士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
Feng Deng,has served as Burning Rock Biotech Limited director since August 2016. Mr. Deng has over 22 years of experience in venture capital, computer science and telecommunication industry. He founded Northern Light Venture Capital in January 2006 and served as its founding managing partner, focusing on investment in technology, media and telecom, or TMT, clean technology, healthcare and consumer sectors. From February 2004 to February 2005, he served as the vice president in strategy in Juniper Networks. From October 1997 to February 2004, Mr. Deng served as the vice president in engineering, chief strategy officer and a director of NetScreen Technologies Inc. Prior to NetScreen, he worked at Intel Corporation as a systems architect from July 1993 to October 1997. He holds a bachelor's and a master's degree in electronic engineering from Tsinghua University, a master's degree in computer engineering from the University of Southern California, and a Master of Business Administration degree from the Wharton Business School of the University of Pennsylvania. - Feng Deng， 自2006年7月起担任公司董事。自2005年12月起担任Northern Light Venture Capital（一家由他联合创立的风险投资公司）管理董事。他持有清华大学电子工程理学学士和硕士学位；南加利佛尼亚大学计算机工程硕士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
- Feng Deng,has served as Burning Rock Biotech Limited director since August 2016. Mr. Deng has over 22 years of experience in venture capital, computer science and telecommunication industry. He founded Northern Light Venture Capital in January 2006 and served as its founding managing partner, focusing on investment in technology, media and telecom, or TMT, clean technology, healthcare and consumer sectors. From February 2004 to February 2005, he served as the vice president in strategy in Juniper Networks. From October 1997 to February 2004, Mr. Deng served as the vice president in engineering, chief strategy officer and a director of NetScreen Technologies Inc. Prior to NetScreen, he worked at Intel Corporation as a systems architect from July 1993 to October 1997. He holds a bachelor's and a master's degree in electronic engineering from Tsinghua University, a master's degree in computer engineering from the University of Southern California, and a Master of Business Administration degree from the Wharton Business School of the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- 汉雨生
汉雨生 是Biotechnology Co., Ltd 创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. Mr. Han has 18 years of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.- 汉雨生 是Biotechnology Co., Ltd 创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
- Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. Mr. Han has 18 years of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.
- Leo Li
Leo Li ，自2019年第三季度起担任Burning Rock Biotech Limited首席财务官，自2020年第一季度起担任Burning Rock Biotech Limited董事。在加入Burning Rock Biotech Limited之前，他曾担任Weidai Ltd.（纽约证券交易所上市的中国领先的汽车支持融资解决方案提供商）的首席财务官。在加入wechat 之前，他曾担任远景骑士资本（Vision Knight Capital，简称VKC，专注于中国互联网驱动行业的私募股权基金）的投资董事和执行董事。加入VKC之前，他在Morgan Stanley Asia Limited 工作。他于2004年至2008年就读于牛津大学（University of Oxford），获得四年物理学硕士学位。他是特许金融分析师。
Leo Li,has served as Burning Rock Biotech Limited chief financial officer since the third quarter of 2019 and Burning Rock Biotech Limited director since the first quarter of 2020. Prior to joining Burning Rock Biotech Limited , Mr. Li served as the chief financial officer of Weidai Ltd., a NYSE-listed leading auto-backed financing solution provider in China. Prior to Weidai Ltd., Mr. Li served as an investment director and later an executive director of Vision Knight Capital, or VKC, a private equity fund focusing on China's internet-driven sectors. Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd. Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree. Mr. Li is a Chartered Financial Analyst.- Leo Li ，自2019年第三季度起担任Burning Rock Biotech Limited首席财务官，自2020年第一季度起担任Burning Rock Biotech Limited董事。在加入Burning Rock Biotech Limited之前，他曾担任Weidai Ltd.（纽约证券交易所上市的中国领先的汽车支持融资解决方案提供商）的首席财务官。在加入wechat 之前，他曾担任远景骑士资本（Vision Knight Capital，简称VKC，专注于中国互联网驱动行业的私募股权基金）的投资董事和执行董事。加入VKC之前，他在Morgan Stanley Asia Limited 工作。他于2004年至2008年就读于牛津大学（University of Oxford），获得四年物理学硕士学位。他是特许金融分析师。
- Leo Li,has served as Burning Rock Biotech Limited chief financial officer since the third quarter of 2019 and Burning Rock Biotech Limited director since the first quarter of 2020. Prior to joining Burning Rock Biotech Limited , Mr. Li served as the chief financial officer of Weidai Ltd., a NYSE-listed leading auto-backed financing solution provider in China. Prior to Weidai Ltd., Mr. Li served as an investment director and later an executive director of Vision Knight Capital, or VKC, a private equity fund focusing on China's internet-driven sectors. Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd. Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree. Mr. Li is a Chartered Financial Analyst.
- 张之宏
张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
Zhihong Zhang,Dr. Zhihong (Joe) Zhang served as Burning Rock Biotech Limited chief technology officer since March 2016. Prior to joining Burning Rock Biotech Limited , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.- 张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
- Zhihong Zhang,Dr. Zhihong (Joe) Zhang served as Burning Rock Biotech Limited chief technology officer since March 2016. Prior to joining Burning Rock Biotech Limited , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.